Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 1 Confidential   
A RAN DOMIZED, VEHICLE -CONTROLLED, SAFETY  
AND EFFICACY STUDY OF EVO101 IN ADULT SUBJECTS  
WITH ATOPIC DERMATITIS  
Protocol Number  EVO101-AD001 
Protocol Final Date  20 April  2022 
Amendment 1 Date  10 June 2022 
Amendment 2 Date  06 January 2023 
Amendment 3 Date  11 May 2023 
Study Drug  EVO101 Topi[INVESTIGATOR_740580], 0.1%  
IND Number  [ADDRESS_1012347] 
Palo Alto , CA 94 304 
[LOCATION_003]  
CONFIDENTIAL INFORMATION  
The information contained herein is confidential and the proprietary property of 
Evommune . Any use or disclosure of such information without the prior written 
authorization of Evommune  is expressly prohibited.  
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 2 Confidential  PROTOCOL AMENDMENT 3.0 SUMMARY OF CHANGES  
Changes to the protocol, introduced in Amendment 3.0, are summarized in the following table. 
Section(s)  Modification  Rationale  
Synopsis  Compariso ns between active and 
vehicle treated arms will be conducted 
using a one -sided test instead of a two-
sided test.  For consistency between the protocol and Statistical Analysis Plan (SAP)  
15.1, 15.4, 15.[ADDRESS_1012348].  For consistency between the protocol and SAP  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 3 Confidential  PROTOCOL AMENDMENT 2.0 SUMMARY OF CHANGES  
Changes to the protocol, introduced in Amendment 2.0, are summarized in the following table. 
Section  Modification  Rationale  
Title Page  Updated Sponsor Address  New headquarters established for 
Evommune (Sponsor)  
6 Updated Schedule of Assessments  For consistency between Table 3 and Section [IP_ADDRESS]  
[IP_ADDRESS]  Provided additional direction on 
recording local skin responses as 
adverse events where appropriate  Clarification for study sites  
15.2 Removed “and received study drug” from the intent -to-treat (ITT) 
population definition  For consistency between the pro tocol 
and Statistical Analysis Plan (SAP)  
15.5.1  Removed “and received study drug” from the ITT population definition  For consistency between the protocol and SAP  
 
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 4 Confidential  PROTOCOL AMENDMENT 1.0 SUMMARY OF CHANGES  
Changes to  the protocol, introduced in Amendment 1.0, are summarized in the following table.  
Section  Modification  Rationale  
1.1 Updated description of inhibitory 
properties of EVO101, primarily as an inhibitor of interleukin 1 receptor -
associated kinase 4; removed characterization as an inhibitor of tropomyosin receptor kinase A  (TrkA) For a more accurate characterization of the primary pharmacology of EVO101  
1.2.1  Removed subsection (formerly [IP_ADDRESS]) that described TrkA For consistency with the primary 
pharmacology of EVO101  
[IP_ADDRESS]  Updated  summary of genotoxicity 
assessment and included results of the Comet test in rats  To provide the most current  safety 
information for EVO101  
[IP_ADDRESS].1  Made minor corrections to the summary of results from Study EVO101 -HV001  To align with final data summarized in the clinical study report  
Procedures in Case of Emergency  Updated Table 1:  Emergency Contact 
[CONTACT_740602]  
[IP_ADDRESS]  Clarified that a ll local skin responses 
should be recorded as adverse events  FDA request  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 6 Confidential  INVESTIGATOR SIGNATURE [CONTACT_1783] 
A RANDOMIZED, VEHICLE- CONTROLLED, SAFETY AND EFFICACY STUDY OF 
EVO101 IN ADULT SUBJECTS WITH ATOPIC DERMATITIS  
Protocol Number : EVO101-AD001 
Protocol Final Date: 20 April 2022 
Amen dment 1 Date:  10 June 2022 
Amendment 2 Date:  06 January 2023 
Amendment 3 Date:  [ADDRESS_1012349] this 
clinical study as outlined in the protocol, according to current Good Clinical Practice and local 
laws and regulations, including those of the [LOCATION_002] (US) Fo od and Drug Administration 
(FDA)  and according to the regulations of the country where the study is being conducted. 
I will ensure that all sub -Investigators and other staff members associated with this study have 
read and understand all aspects of this pr otocol.  
I have read and understand all study related information provided to me.  
The objectives and conduct of this protocol as well as the results deriving from this study will be 
treated confidentially and will not be made available to third parties without prior authorization by [CONTACT_740603]. All rights of publication of the results reside with Evommune unless other 
agreements were made in a separate contract.  
  
_____________________________________ _______________________ 
Investigator’s  Signature [CONTACT_1782]  
 
 
_____________________________________ 
Investigator’s Name (print)  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 8 Confidential  SYNOPSIS   
Name [CONTACT_790]/Company:  Evommune, Inc.  
Name [CONTACT_791]: EVO101 Topi[INVESTIGATOR_740581], 0.1%  
Protocol Number:  
EVO101 -AD001  Phase: 2a Country:  [LOCATION_003] 
Title of Study: A RANDOMIZED, VEHICLE -CONTROLLED, SAFETY AND EFFICACY STUDY 
OF EVO101 IN ADULT SUBJECTS  WITH ATOPIC DERMATITIS  
Objectives:  
Primary: Assess the safety, tolerability, and preliminary efficacy of EVO101 Topi[INVESTIGATOR_740580], 0.1%, 
applied twice daily in adults with atopic dermatitis  (AD) . 
Secondary:  The secondary objective of this study will be to assess the pharmacokinetics of EVO101 
Topi[INVESTIGATOR_740580] 0.1%, applied twice daily in  adults with AD. 
Study Design:  Randomized, Double -Blind, Parallel Group, Vehicle Controlled  
Number of subjects (planned): 118 
Diagnosis and main criteria for inclusion: A dults with mild to moderate AD  
Investigational product, dosage,  and mode of administration: EVO101 Topi[INVESTIGATOR_740580], 0.1% twice 
a day ( BID) 
Duration of treatment: 8 weeks  
Reference therapy, dosage,  and mode of administration: EVO101 Topi[INVESTIGATOR_740580],  Vehicl e BID  
Criteria for evaluation:  
Efficacy: Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), Body 
Surface Area (BSA), Pruritus -Numerical Rating Scale (NRS ) 
Safety: Adverse Event (AEs), Local Skin Response (LSRs), Physical Exam,  Serum Chemistry, 
Hematology and Urinalysis, ECG  
Pharmacokinetics : Plasma drug concentrations  
Statistical methods: Sample size justification: 
The assumed true standard deviation of the percentage change from Baseline to Week 8 in the EASI 
score is 50%.  Based on the use of a one -sided test  at the alpha=0.05 level of significance, a total 
sample size of 1 18 subjects (59 subjects/treatment arm ) will provide  greater than  90% power to detect 
a mean between -group difference of 30 percentage points.  
Primary efficacy analysis:  
The primary efficacy analysis will be conducted in the intent -to-treat population (all randomized  
subject) using  an analysis of variance (ANOVA) model with the percentage change from  Baseline to 
Week [ADDRESS_1012350] at the alpha=0.05 level of 
significance. 
Secondary efficacy analyses:  
All secondary endpoints defined as the percentage change from Baseline will be analyzed using the 
same type of ANOVA model as specified for the primary analysis. All change from Baseline 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 9 Confidential  secondary endpoints will be analyzed using analysis of covariance (ANCOVA) models with treatment 
group and the randomization stratif ication variable as factors and with the baseline value of the 
corresponding endpoint as a covariate. Secondary endpoints that are defined as proportion variables 
will be analyzed using Pearson’s chi -square test or (if more than 25% of expected cell frequencies are 
less than 5) Fisher’s exact test. All secondary analyses will be conducted using one -sided tests at the 
alpha=0.05 level of significance, with no adjustments for multiplicity.  
 
  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 10 Confidential  TABLE OF CONTENTS  
PROTOCOL AMENDMENT 3.0 SUMMARY OF CHANGES  ....................................................2  
PROTOCOL AMENDMENT 2.0 SUMMARY OF CHANGES  ....................................................3  
PROTOCOL AMENDMENT 1.0 SUMMARY OF CHANGES  ....................................................4  
SPONSOR SIGNATURE [CONTACT_1783]  ....................................................................................................5  
INVESTIGATOR SIGNATURE [CONTACT_1783]  .........................................................................................6  
PROCEDURES IN CASE OF EMERGENCY  ...............................................................................7  
SYNOPSIS  .......................................................................................................................................8  
1. INTRODUCTION  ......................................................................................................16  
  
  
  
  
  
  
  ..........................................................................................20  
1.3. Study Rationale ...........................................................................................................21  
2. STUDY OBJECTIVES  ..............................................................................................22  
2.1. Primary Objective  .......................................................................................................22  
2.2. Secondary Objectives  .................................................................................................22  
3. STUDY ENDPOINTS  ................................................................................................23  
3.1. Efficacy Endpoints ......................................................................................................23  
3.2. Pharmacokinetic Endpoints ........................................................................................23  
4. INVESTIGATIONAL PLAN  .....................................................................................24  
4.1. Overall Study Design  ..................................................................................................24  
4.2. Study Population and Number of Subjects .................................................................24  
4.3. Duration of the Study ..................................................................................................24  
5. STUDY DESIGN SCHEMATIC  ...............................................................................25  
6. SCHEDULE OF ASSESSMENTS  .............................................................................26  
7. SELECTION OF SUBJECTS  ....................................................................................27  
7.1. Inclusion Criteria  ........................................................................................................27  
7.2. Exclusion Criteria  .......................................................................................................28  

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 11 Confidential  8. STUDY DRUG  ...........................................................................................................29  
8.1. Description of Study Drug ..........................................................................................29  
8.2. Study Drug Packaging and Labelling .........................................................................29  
8.3. Study Drug Storage .....................................................................................................29  
8.4. Randomization and Blinding ......................................................................................29  
8.5. Study Drug Administration and Application ..............................................................29  
8.6. Study Drug Dispensing and Return ............................................................................30  
8.7. Study Drug Compliance .............................................................................................30  
8.8. Study Drug Accountability and Disposal ...................................................................30  
9. CONCOMITANT MEDICATIONS AND PROCEDURES  ......................................31  
9.1. Permitted Treatments and Procedures ........................................................................31  
9.2. Prohibited Treatments and Procedures .......................................................................31  
10. STUDY PROCEDURES BY [CONTACT_16990]  ..........................................................................32  
10.1.  Screening Period .........................................................................................................32  
10.2.  Baseline (Day 1)  .........................................................................................................32  
10.3.  Week 2  ........................................................................................................................33  
10.4.  Week 4  ........................................................................................................................33  
10.5.  Week 8 (Study Exit/Early Withdrawal)  ......................................................................34  
10.6.  Unscheduled Visit .......................................................................................................34  
11. ASSESSMENT OF EFFICACY  ................................................................................35  
11.1.  Investigator Global Assessment (vIGATM) .................................................................35  
11.2.  Eczema Severity and Area Index (EASI)  ...................................................................35  
11.3.  Body Surface Area (BSA) Involvement .....................................................................36  
11.4.  Pruritus -NRS Scale  .....................................................................................................36  
12. BASELINE DEMOGRAPHICS, ATOPIC DERMATITIS AND MEDICAL 
HISTORY  ...................................................................................................................37  
12.1.  Demographics and Other Baseline Characteristics  .....................................................37  
12.1.1.  Atopic Dermatitis Prior Medications History  .............................................................37  
12.1.2.  Other Atopic Diseases History  ...................................................................................37  
12.2.  Medical History  ..........................................................................................................37  
13. ASSESSMENT OF SAFETY  .....................................................................................38  
13.1.  Safety Parameters  .......................................................................................................38  
13.1.1.  Vital Signs  ..................................................................................................................38  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 12 Confidential  13.1.2.  Physical Examination  .................................................................................................38  
13.1.3.  Electrocardiogram (ECG) ...........................................................................................38  
13.1.4.  Laboratory Assessments  .............................................................................................38  
[IP_ADDRESS].  Local Skin Reactions (L SRs)  ......................................................................................39  
13.2.  Adverse and Serious Adverse Events  .........................................................................40  
13.2.1.  Definition of Adverse Events .....................................................................................40  
[IP_ADDRESS].  Adverse Event (AE) ....................................................................................................40  
[IP_ADDRESS].  Serious Adverse Event (SAE)  ....................................................................................40  
13.2.2.  Reporting of Adverse Events ......................................................................................41  
13.2.3.  Reporting of Serious Adverse Events  .........................................................................42  
13.2.4.  Relationship to Study Drug ........................................................................................43  
13.3.  Pregnancy Testing ......................................................................................................43  
13.4.  Pharmacokinetic Sampling .........................................................................................43  
14. STUDY DISCONTINUATIONS  ...............................................................................44  
14.1.  Discontinuation of the Study ......................................................................................44  
14.2.  Early Withdrawal of Study Subjects  ...........................................................................44  
14.3.  Study Drug Discontinuation .......................................................................................45  
15. STATISTICAL CONSIDERATIONS .......................................................................46  
15.1.  General Statistical Methodology  ................................................................................46  
15.2.  Populations Analyzed  .................................................................................................46  
15.3.  Exposure and Compliance ..........................................................................................47  
15.4.  Efficacy Measures  ......................................................................................................47  
15.4.1.  Primary Efficacy Analysis  ..........................................................................................47  
15.4.2.  Secondary Efficacy Analyses  .....................................................................................47  
15.5.  Adverse Events ...........................................................................................................47  
15.5.1.  Local Skin Reactions  ..................................................................................................48  
15.6.  Other Safety Data  .......................................................................................................48  
15.7.  Pharmacokinetic Analysis  ..........................................................................................48  
15.8.  Sample Size Determination  ........................................................................................48  
16. ACCESS TO SOURCE AND STUDY RELATED DOCUMENTS  .........................49  
16.1.  Study Monitoring ........................................................................................................49  
16.2.  Audits and Inspections ................................................................................................49  
17. ETHICS  ......................................................................................................................50  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012351] OF TABLES  
Table 1:  Emergency Contact [CONTACT_7171]  ...................................................................................7  
Table  2: Estimated Safety Margins Based on Animal to Human Dose Multiples  ....................19  
Table  3: Schedule of Assessments  ............................................................................................26  
Table  4: vIGA ...........................................................................................................................35  
Table  5: Subject Assessed Local Skin Reactions .....................................................................40  
Table  6: Investigator Assessed Local Skin Reactions  ..............................................................[ADDRESS_1012352] OF FIGURES  
Figure 1:  IRAK4 Functions Downstream of TLR and IL-1 Family Cytokine Receptors ..........17  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012353]  
DRF  dose range -finding 
DS drug substance  
EASI  eczema area and severity index  
ECG  electrocardiogram  
eCRF  electronic case report form  
FDA Food and Drug Administration 
GCP  good clinical practices  
GLP good laboratory practices  
HED human equivalent dose  
ICF informed consent form  
ICH International Council for Harmonization  of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC International ethics committee  
IGA investigator global assessment  
IL interleukins  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012354] Term  Explanation  
IND Investigational New Drug  
IR infrared (spectrophotometry)  
IRAK4  interleukin [ADDRESS_1012355]  
ITT intent -to-treat 
IWRS  interactive web -based randomization system  
kg kilogram  
LSR local skin response  
MedDRA  medical dictionary for regulatory activities  
mg milligram  
mL milliliter  
mmHg  millimeters of mercury  
MyD88  myeloid differentiation primary response gene 88  
NF-kB nuclear factor -kappa B  
ng nanograms  
NGF  nerve growth factor  
NOAEL  no-observed -adverse- event -level  
NRS  numerical rating scale  
PK pharmacokinetics  
ppm parts per million  
PI [INVESTIGATOR_740582](s)  
SD standard deviation  
Th T helper type  
TLR toll-like receptor  
TEAE treatment emergent adverse event  
TRPV1  Transient Receptor Membrane Potential cation channel subfamily V 
member 1  
US [LOCATION_002]  
VEGF  vascular endothelial growth factor  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 16 Confidential  1. INTRODUCTION  
1.1.  
  
 
 
  
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 17 Confidential    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 18 Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 19 Confidential   
 
  
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
 
 
        
        
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 20 Confidential  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 21 Confidential  1.3. Study Rationale  
Study EVO101-AD001 is planned as a randomized, double- blind ed, parallel group proof-of-
concept trial in which safety,  preliminary efficacy and pharmacokinetics will be assessed.  
Approximately 118 adult subjects with mild -to-moderate AD will be randomized  and apply 
study drug or vehicle to  their affec ted areas twice daily for 8 weeks. This dos ing regimen has 
been selected because it was found to be well -tolerated in a previous study, EVO101- HV001 , 
conducted in adult healthy volunteers.  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 22 Confidential  2. STUDY OBJECTIVES  
2.1. Primary Objective 
The primary  objective of this study will be to assess the safety , tolerability,  and preliminary 
efficacy of EVO101 Topi[INVESTIGATOR_740580], 0.1%, applied twice daily, in adults with AD. 
2.2. Secondary Objectives  
The secondary objective of this study will be to assess the pharmacokinetics of EVO101 Topi[INVESTIGATOR_740583] , 0.1%, applied twice daily, in adults with AD.  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 23 Confidential  3. STUDY ENDPOINTS  
3.1. Efficacy  Endpoints 
The primary efficacy endpoint for this trial will be:  
• Mean percentage change from Baseline in EASI score at Week 8 
Secondary efficacy endpoi nts for this study will be:  
• IGA response (≥2 point change from baseline) at Week 8 
• Change from B aseline in IGA at Week 8 
• Mean change from Baseline in BSA affected at Week 8 
Exploratory efficacy endpoints for this study will be:  
• EASI -75 and EASI-90 from Baseline to Week 2 , 4 and 8 
• Mean change from Baseline in EASI at Weeks 2 and 4 
• Proportion of subjects achieving an I GA score of [ADDRESS_1012356] an improvement of 
≥ 2 points from Baseline at Week 8 
• Change from Baseline in IGA score at Weeks 2 , 4 and 8 
• Mean change from Baseline in the pruritus- NRS  score at Weeks, 2 , 4 and 8 
• Mean and percentage change from Baseline in the pruritus- NRS score at Week 8 
• Proportion of subjects achieving a 4- point improvement in the pruritus -NRS score 
from Baseline to Week 8 
• Mean change from Baseline in BSA affected at Weeks, 2 , 4 and 8 
3.2. Pharmacokinetic Endpoints  
Plasma levels of EVO101 at B aseline, W eek 2 and  8. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 24 Confidential  4. INVESTIGATIONAL P LAN  
4.1. Overall Study Design 
The study is a randomized, double- blind ed, vehicle controlled, parallel group study, designed to 
assess the safety, tolerability, and preliminary efficacy of EVO101 Topi[INVESTIGATOR_740580], 0.1%, in 
subjects with mild -to-moderate AD.   
Approximately 118 adult subjects, ≥ [ADDRESS_1012357]  is expected to be approximately 12 weeks (up to 4 weeks screening, 
8 weeks treatment).  
Subjects will be in generally good health and have a clinical diagnosis of mild- to-moderate AD 
for at least one y ear, an IGA score of 2 or 3, an EASI of 5-20, and an affected BSA of 4-12%. 
Subjects must be willing to discontinue any therapi[INVESTIGATOR_740584], other than the investigational product, during the trial. Subjects will be randomized (1:1), at Baseline, to one of two treatment arms: EVO101 Topi[INVESTIGATOR_740580], 0.1%, or vehicle cream. The randomization will be stratified by  [CONTACT_740604] (IGA 2 , IGA 3).  At 
most 40% of randomized subjects can be in the IGA 2 stratum.  
Subjects will be instructed to apply a thin layer of study drug to the affected areas, twice daily, during their trial participation.   
Subjects will participate in the trial for 8 weeks in duration and be seen for in- clinic visits at 
Screening (up to 30 days prior to Baseline), Baseline, Week 2, Week 4 and Week 8 (Study Exit).  
Efficacy will be assessed using the IGA for AD (scored from 0 -4), EASI, percentage BSA 
affected, and pruritus (using an  11-point pruritus -NRS ; assessing the worst itch in the last 
24-hours, by [CONTACT_423] , daily).  
Safety will be assessed through physical exam, serum chemistries, hematology, urinalysis, 
ECGs, AEs , and local skin reactions.  
Pharmacokinetic samples will be collected at Baseline, Week 2 and Week 8. 
4.2. Study Population and Number of Subjects  
Approximately 118 subjects with AD that are ≥[ADDRESS_1012358] is expected to be approximately 12 weeks (up to 
4 weeks screening, 8 weeks treatment).  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 25 Confidential  5. STUDY DESIGN SCHEMATIC 
 

Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 26 Confidential  6. SCHEDULE OF ASSESSMENTS  
Table  3: Schedule of Assessments  
Visit Screening 
Day -30 to -1 Baseline 
Day 1 Week 2  Week 4  Week 8 
Study Exit/  
Early 
Withdrawal Unscheduled 
Visit 
Visit Window   +/- 1 day +/- 2 days  +/- 4 days   
Informed Consent  X      
Demographics X      
Medical History  X X     
Inclusion/Exclusion Criteria  X X     
Physical Exam  X X   X X2 
Height and Weight  X      
Serum Chemistry, 
Hematology, Urinalysis  X    X X2 
Urine Pregnancy Test  X X X X X X2 
Vital Signs  X X X X X X2 
COVID-19 Test4 X     X2 
12-lead ECG  X    X X2 
Adverse Events  X X1 X X X X2 
Local Skin Reactions   X1 X X X  
Concomitant Medications  X X X X X X2 
IGA X X X X X  
BSA  X X X X X  
EASI  X X X X X  
Pruritus-NRS (e-diary) X3 X X X X  
Pharmacokinetic Sample   X X  X  
Dispense Study Drug  X X X  X2 
Study Drug Compliance    X X X  
1 LSRs collected pre -application and 15 minutes following application on Baseline /Day 1  (see Section [IP_ADDRESS]  for details on 
LSR assessment
).  
[ADDRESS_1012359] to be performed within Day -4 to -1 or at the Baseline visit . 
 
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012360] meet all of the following criteria to be eligible for study participatio n: 
1. Signed informed consent. 
2. Willing and able to comply with the study visit schedule, procedures,  and questionnaires.  
3. Male or non-pregnant, non- lactating, females, age ≥18 years.  
4. Chronic AD (according to the American Academy of Dermatology Consensus Criter ia) 
that has been present for ≥1 year before the S creening visit.  
5. Investigator's Global Assessment score of 2 to 3 at S creening and Baseline.  
6. EASI of 5 -20 at screening and baseline.  
7. BSA of AD involvement, excluding the face and intertriginous areas, of 4% to 12% at 
Screening and Baseline.  
8. Application of a stable dose of non- medicated topi[INVESTIGATOR_740585] ≥7 days 
prior to the Baseline visit and willing to maintain stable  dosing during study participation 
9. Completed electronic diary entries for pruritus for a minimum of 4 of 7 days preceding randomization at the Baseline visit.  
10. Willing to use effective contracepti ve method, if applicable, during study participation 
and for 30 days following the end of treatment.  
For women of childbearing potential: agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least [ADDRESS_1012361] applic ation of study drug.  
A woman of childbearing potential is defined as a postmenarcheal female, who has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical st erilization 
(removal of ovaries and/or uterus).  
The following are highly effective contraceptive methods: combined (estrogen and 
progestogen containing) hormonal contraception (oral, intravaginal, transdermal) 
associated with inhibition of ovulation, progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone -releasing system (IUS), bilateral tubal occlusion, vasectomized 
partner, or sexual abstinence. The reliability of sexual abstinence should be evalua ted in 
relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. Females must agree not to donate ova during the study and for 30 days after the end of study visit.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012362] agree not to donate 
sperm  during the study and for 30 days after the end of study visit. 
7.2. Exclusion Criteria  
Subjects meeting any of the following criteria are  not eligible for study participation: 
1. Significant AD flare, in the opi[INVESTIGATOR_689], within 4 weeks prior to Baseline. 
2. Use of biologic therapy (e.g., dupi[INVESTIGATOR_12458]) within 12 weeks or 5 half- lives prior to 
Baseline.  
3. Use of topi[INVESTIGATOR_740586], calcineurin inhibitors or phosphodiesterase- 4 inhibitors within 2 weeks prior to the Baseline visit.  
4. Use of systemic antibiotics within 2 weeks of Baseline.  
5. Use of prescription moisturizers within 7 days  of the Baseline visit.  
6. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the Screening visit.   
7. Presence of skin comorbidities or other condition that may interfere with study assessments.  
8. Active participation in an experimental therapy study or who received experimental therapy within 30 days or 5 half- lives (whichever is longer) before Baseline.  
9. Screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opi[INVESTIGATOR_689].  
10. Abnormal findings on screening ECG, deemed clinically significant by [CONTACT_737]. 
11. Positive COVID -[ADDRESS_1012363] be  done , after discussion with the sponsor’s Medical 
Monitor.  
12. COVID vaccination (last dose) within 2 weeks of start of Screening. 
13. Systemic immunosuppressive or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate -mofetil, IFN -γ, Janus kinase inhibitors, 
azathioprine, methotrexate, etc.) or phototherapy and photochemotherapy (PUVA) within [ADDRESS_1012364] at unacceptable risk for participation in the study. 
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012365] AD Mappi[INVESTIGATOR_740587] ( Appendix 1) to identify and map all 
AD affected areas for each respective subject enrolled. A copy of the diagram will be given to 
each subject  to use as a guide when  applying study  drug at home . Patients must apply study drug 
to the same affected areas throughout the study, even though their AD disease may improve or 
clear during the study. Subjects will be instructed to apply study drug to any new AD lesions, 
should they occur. The original diagram will be retained as a source document.   
The first dose of the study drug will b e applied at  the study site for instructional purposes and 
will be recorded in the dosing diary as the first dose. Subjects will apply the study drug twice daily, in the morning and evening for a total of [ADDRESS_1012366] only be dispensed from official study sites by [CONTACT_740605].  
Subjects should return their used and unused study drug at the ir next study site  visit  for study 
drug accountability purposes. Subjects may be re -dispensed unused study medication.  
Subjects are to return all their study drug (used or  unused) to the study site at the end of study 
participation . Study staff will record tubes dispensed and returned, by [CONTACT_740606].  
Each subject  is to be instructed on th e importance of returning study drug to the study site  at their 
final study visit. Subjects who fail to return their study drug will be directed  to return it as soon 
as possible.  
8.7. Study Drug Compliance  
Treatment compliance will be assessed  by [CONTACT_423], daily,  using an e- diary . A subject 
deviating significantly (less than 80% compliant)  from the twice daily dosing regimen will be 
counseled  or terminated from the trial, at the discretion of the Investigator. Study site staff will 
monitor subject compliance  regularly.  
8.8. Study Drug Accountability and Disposal  
The Investigator or designee will be responsible for documenting drug accountability at the site. 
Study drug accountability records will document the receipt, dispensing and return of study drug 
and provide a complete account of all used and unused drug product.  
Study drug accountability records will be reviewed by [CONTACT_16015]. Following final 
accountability, instructions will be provided to the site regarding study drug return and 
destruction .  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 31 Confidential  9. CONCOMITANT MEDICATIONS AND PROCEDURES  
All medications , including over- the-counter drugs, vitamins, antacids, and skin care products, 
taken during screening and throughout the study will be recorded i n the eCRF .  
Medication entries should be specific to  the generic name (if a combination drug, then marketed 
product name) and will include the dose, unit, and frequency of administration and/or treatment, 
route of administration, start date, discontinuation date, and indication.  
The Investigator should exa mine the acceptability of all concomitant procedures, medications, 
topi[INVESTIGATOR_12469],  and dietary supplements not explicitly prohibited in this study.  
In order to ensure that appropriate concomitant therapy is administered, subjects will be 
instructed to consult with the Investigator prior to taking any medication (either self-
administered non -prescription drugs or prescription therapy prescribed by [CONTACT_20427]). 
9.1. Permitted Treatments and Procedures  
The use of concomitant medications for the treatment of an AE is permitted during this study.  
Moisturizer  Use: 
• Non-medicated moisturizer must be used during trial participation, twice daily (may be 
applied at the time of study drug application), to all non- affected areas.  
• Sunscreens may be used on all areas provided the application occurs at least 15 minutes 
following study drug application.  
• Subjects are asked to avoid the use of moisturizers and sunscreens prior to the study visit 
but may use these products following study visits.  
Concomitant medications for mild -to-moderate asthma, allergic rhinitis and allergies  are 
permitted.  Concomitant medications for the treatment of any other diseases except those 
prohibited concomitant medi cation s listed  in Section  10.2 are permitted . The medical monitor 
may be consulted if needed for questions on permitted and prohibited treatments and procedures.  
9.2. Prohibited Treatments and Procedures 
Subjects should not undergo any elective medical procedure without prior consultation with the 
Investigator. Elective out- patient procedures (e.g., minor outpatient surgery) that might require 
hospi[INVESTIGATOR_740588].  
The following medications and treatments are prohibited during the study:  
• Any prescription or over-the- counter product intended to treat AD.  
• Use of tanning booth. 
• Excessive s un exposure. 
The medical monitor may be consulted if needed for questions on permitted and prohibited 
treatments and procedures. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012367] evaluation at each study visit are outlined below and in the 
study Schedule of Visits and Procedures. The timing of each study day is relative to the day of 
initial dosing /application  (Baseline/Day 1 ). Visit windows are provided, where allowed, to a llow 
study sites flexibility in maintaining the study visit schedule for participating subjects.  
10.1. Screening Period 
The screening evaluation period may take up to [ADDRESS_1012368] eligibility will be referred to the Sponsor or their designee. Screen failures may not be re-screened  unless approved by [CONTACT_1034].  
• Obtain written informed consent.  
• Collect demographic information . 
• Complete medical history . 
• Review inclusion/exclus ion criteria . 
• Query subject for prior and concomitant medication use. 
• Perform a physical examination . 
• Record height and weight. 
• Measure vital signs.  
• COVID-[ADDRESS_1012369]. 
• 12-lead ECG . 
• Draw blood samples for laboratory tests  and urine for urinalysis and urine pregnancy 
test. 
• Collect IGA, BSA and EASI.  
• Upload and instruct on e- diary for  pruritus -NRS . 
• Collect AEs  
• Schedule next visit. 
10.2. Baseline (Day 1) 
• Collect concomitant medication information . 
• Measure vital signs. 
• Medical history: update medical history if appropriate.   
• Perform a physical examination . 
• Conduct urine pregnancy test.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 33 Confidential  • Draw blood sample for pharmacokinetic analysis.  
• Collect IGA , BSA and EASI . 
• Collect AEs . 
• Collect LSRs  pre and post study drug application. 
• Confirm pruritus -NRS diary data is complete . 
• Confirm subject eligibility and enrollment. 
• Instruct subject on study medication application and e-diary completion. 
• Apply first application in clinic and record in diary.  
• Dispense study drug and Subject AD Mappi[INVESTIGATOR_740587]. 
• Schedule next visit. 
10.3. Week 2  
• Collect AEs  
• Collect concomitant medication information . 
• Measure vital signs. 
• Conduct urine pregnancy test.  
• Draw blood sample for pharmacokinetic analysis.  
• Collect IGA, BSA and EASI . 
• Collect LSRs . 
• Confirm compliance with  pruritus- NRS diary .  
• Confirm compliance with study drug application . 
• Dispense study drug. 
• Schedule next visit. 
10.4. Week 4 
• Collect AEs  
• Collect concomitant medication information . 
• Measure vital signs. 
• Conduct urine pregnancy test.  
• Collect IGA, BSA and EASI . 
• Collect LSRs . 
• Confirm compliance with pruritus -NRS diary . 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 34 Confidential  • Confirm compliance with study drug application . 
• Dispense study drug. 
• Schedule next visit. 
10.5. Week 8 (Study Exit/Early Withdrawal ) 
• Perform physical exam.  
• Collect AEs . 
• Collect concomitant m edication information . 
• Measure vital signs. 
• Collect ECG.  
• Draw blood samples for laboratory tests  and urine for urinalysis and urine pregnancy 
test. 
• Draw blood sample for pharmacokinetic analysis.  
• Collect IGA, BSA and EASI . 
• Collect LSRs . 
• Confirm compliance with pruritus- NRS diary . 
• Confirm compliance with study drug application . 
• Close e- diary  and exit subject from study . 
10.6. Unscheduled Visit  
Additional visits may  be scheduled as necessary to ensure the safety and well -being of subjects 
who experience AEs. Physical exam  and laboratory evaluations, if necessary, should be 
conducted. Laboratory evaluations should be collected and analyzed using the central laboratory 
for this study. Data will be recorded in the eCRF.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 35 Confidential  11. ASSESSMENT OF EFFICACY 
11.1. Investigator Global Assessment (vIGATM) 
The IGA is a static assessment and rates the severity of the subject’s AD and is a 5 -point scale 
ranging from 0 (clear) to 4 (severe).  A score is selected using descriptors that best describe the 
overall appearance of the lesions at a given time point. It is not necessary that all characteristics 
under the morphological description be present. A single assessor should be assigned to each 
individual subject for as many visits as possible, to avoid inter- assessor variability in scoring. 
Assessors must be trained and certified by [CONTACT_143215]. The 
IGA must be conducted prior to conducting EASI and BSA assessments.  
The IGA score is selected using the descriptors below that best describe the ov erall appearance 
of the lesions at a given time point.  
Table  4: vIGA 
Score  Clinical Definition1,2 
0-Clear  No inflammatory signs of atopic dermatitis (no erythema, no 
induration/papulation, no lichenification, no oozing/crusting). Post -inflammatory 
hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_22765].  
1-Almost clear  Barely perceptible erythema, barely perceptible induration/papulation, and/or 
minimal lichenification. No oozing or crusting . 
2-Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite induration/papulation, 
and/or slight but definite lichenification. No oozing or crusting.  
3-Moderate Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, 
and/or clearly perceptible lichenification. Oozing and crusting may be present.  
4-Severe Marked erythema (deep or bright red), marked induration/papulation, and/or 
marked lichenification. Disease is widespread in extent. Oozing or crusting may 
be present.  
1 In indeterminate cases, please use extent to differentiate between scores.  
2 Excoriations should not be considered when assessing disease severity  
Copyright ©2017 Eli Lilly and Company – Used with the permission of Eli Lilly and Company under a Creative 
Commons Attribution -NoDerivatives 4.0 International License - https://creativecommons.org/licenses/by -nd/4.0/  
11.2. Eczema Severity and Area Index (EASI)  
EASI is used to assess the severity and extent of AD; it is a composite index with scores ranging 
from 0 to 72, with the higher values indicating more severe and/or extensive disease. Assessors 
must be trained and certified by [CONTACT_143215].  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 36 Confidential  11.3. Body Surface Area (BSA) Involvement  
The BSA assessment estimates the extent of disease or skin involvement with respect to AD and 
is expressed as a percentage of total body surface. BSA will be determined by [CONTACT_740607] = 1% rule. Assessors must be trained and certified by [CONTACT_143215]. 
11.4. Prurit us-NRS Scale 
Pruritus will be assessed using a Pruritus Numerical Rating Scale (NRS). The Pruritus NRS is an 11-point scale used by [CONTACT_740608] 24 hours with 0 
indicating “No itch” and 10 indicating “Worst itch imaginable.” Subject assessments will be 
captured daily using an electronic diary.  
Subjects will be provided with an electronic diary at least  [ADDRESS_1012370] to be eligible for study participation.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012371] or coexisting medical conditions (including COVID-19 infection and 
vaccination) or surgeries. The medical history will be updated prior to treatment at  Baseline 
should new findings be present since the screening visit. Findings will be recorded in the eCRF. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 38 Confidential  13. ASSESSMENT OF SAFETY  
13.1. Safety Parameters  
13.1.1. Vital Signs  
Vital signs, including body temperature, respi[INVESTIGATOR_697] (breath per minute), pulse (beats per 
minute), and blood pressure (mmHg), will be obtained with the subject in the seated position, after sitting for at least [ADDRESS_1012372]’s weight will be recorded with the end of study physical exam. Findings will be recorded in the eCRF.  
13.1.3. Electrocardiogram (ECG)  
12-lead ECG measurements will be obtained in all subjects. The subject should rest quietly for at 
least [ADDRESS_1012373] eligibility. 
The medical monitor may be consulted if needed for interpretation of ECGs.  
All study sites will be supplied with standardized, validated digital 12 -lead ECG (12 lead at 
25 mm/sec reporting rhythm, ventricular rate, the RR interval, the PR interval, QRS duration, 
QT, QTcF  and QTcB intervals) equipment capable of recording, storing, and printing producing 
high resolution 12- lead ECG. Study sites will be trained on the use of the equipment prior to 
study start.  
Machine -read ECG recordings will be collected and analyzed centrally. Data will be transferred 
electronically to the database.  Additional details regarding subject preparation, ECG 
procurement and data transmission may  be provided in a separate study m anual.  
13.1.4. Laboratory Assessments  
Laboratory tests will be collected to evaluate safety in all study subjects and analyzed using a 
central laboratory. Lab oratory samples will be collected per the Schedule of Visits and 
Procedures, and as clinically indicated . Laboratory samples are to be shipped on the same day as 
collected.  Laboratory tests are described below.  
COVID-19: molecular (RT -PCR) test or antigen  test for COVID -19 infection. 
Hematology: hematocrit, hemoglobin, red blood cell (RBC) count, white blood cell count and 
differential (%), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 39 Confidential  concentration (MCHC), mean corpuscular volume, RBC morphology, platelet count, absolute 
neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, and absolute 
basophils. 
Chemistry: sodium, potassium, chloride, calcium, phosphorus, bicarbonate, uric acid, blood urea 
nitrogen (BUN), creatinine, total protein, albumin, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase, bilirubin (total and direct), and non- fasting 
glucose. 
Urine pregnancy testing (beta human chorionic gonadotropin [β -hCG]): performed in all fe males 
unless post- menopausal/sterile.  
Urinalysis: pH, specific gravity, protein, glucose, ketones, bilirubin, blood, nitrite, urobilinogen, 
leukocyte esterase. A microscopic examination of urine will be performed if clinically indicated 
in the opi[INVESTIGATOR_740589]. Any clinically significant laboratory result is to be recorded as an AE after study drug dosing. 
Screening laboratory values must be reviewed by [CONTACT_740609]. 
Subjects will be screen failed for clinically significant laboratory values. Screening laboratory 
tests may be repeated  one time  in order to confirm out of range results  or clinical significance at 
the discretion of the investigator. Subjects with a positive test result for COVID-[ADDRESS_1012374] result will 
be evaluated by [CONTACT_978] [CONTACT_1629] d will be treated and/or followed up at the discretion of the PI [INVESTIGATOR_740590]. 
[IP_ADDRESS]. Local Skin Reactions (LSRs)  
A static assessment of local skin reactions will be conducted in all subjects at each study visit.  
LSRs include burning/stinging, pruritus, edema, erythema, dryness and scaling. Each LSR will 
be scored as 0  (None), 1 (Mild), 2  (Moderate) or 3 (Severe).  
Burning/stinging and pruritus will be assessed by [CONTACT_656550]/swelling, erythema, 
dryness, a nd scaling will be assessed by [CONTACT_737]/designee. Subjects will be read the 
definition of each subject- assessed LSR and asked to select the appropriate definition. The 
corresponding grade will be assigned by [CONTACT_294728]. 
At the  Baseline visit, LSRs are collected prior to study drug application and approximately 
15 minutes (+30 minutes) following the first application of study drug.  
When assessing the LSRs, the underlying disease involving the skin should be considered in the 
overall scor e.  Local skin reaction  assessments subsequent to study drug application, that are 
greater than the Baseline visit pre -application  assessment  score are to be recorded as an AE.   The 
stop date for the AE is the date that the score is less than or equal to the pre- application  Baseline 
Day 1 visit score.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 40 Confidential  Table  5: Subject Assessed Local Skin Reactions 
Score  Grade  Burning/Stinging  Pruritus  
0 None  No stinging/burning No pruritus  
1 Mild  Slightly warm, tingling sensation; not 
really bothersome  Occasional, slight itching/scratching  
2 Moderate  Definite warm; tingling/stinging 
sensation that is somewhat bothersome  Intermittent itching/scratching which does not disturb sleep  
3 Severe Hot, tingling/stinging  sensation that has 
caused definite discomfort  Bothersome itching/scratching which disturbs sleep  
Table  6: Investigator Assessed Local Skin Reactions  
Score  Grade  Edema  Erythema  Dryness  Scaling  
0 None  No edema No erythema 
present  None  None  
1 Mild  Slight, barely perceptible edema  Slight erythema: very light -pi[INVESTIGATOR_740591]  
[ADDRESS_1012375] presence of edema  Dull red, clearly distinguishable  Easily noted dryness and flakes but no fissure formation Diffuse scaling  
3 Severe Marked, intense edema  Deep/dark red  Easily noted 
dryness with flakes 
and fissure formation Prominent, dense scaling  
13.2. Adverse and Serious Adverse Events 
13.2.1. Definition of Adverse Events  
[IP_ADDRESS]. Adverse Event (AE)  
An AE is the development of an undesirable medical condition or the deterioration of a pre -
existing medical condition following or during exposure to a pharmaceutical product, whether or 
not considered casual ly related to the product. In clinical studies, an AE can include an 
undesirable medical condition occurring at any time, including baseline or washout periods, even 
if no study treatment has been administered. 
[IP_ADDRESS]. Serious Adverse Event (SAE)  
An AE  or suspected AE  reaction is considered serious if, in the view of either the Investigator or 
Sponsor, it results in any of the following outcomes: 
• Death; 
• Immediately life -threatening ; 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 41 Confidential  An AE  or suspected AE  is considered “life threatening” if, in view of either the 
Investigator or Sponsor, its occurrence places the study subject at immediate risk of 
death. It does not include an event that, had it occurred in a more severe form, might have 
caused death.  
• Requires in -patient hospi[INVESTIGATOR_1081] . 
Any hospi[INVESTIGATOR_740592]- patient hospi[INVESTIGATOR_059], regardless of 
duration. An emergency room visit without hospi[INVESTIGATOR_740593], nor will hospi[INVESTIGATOR_272] a procedure scheduled before signing of informed consent. However, unexpected complications and/or prolongation of 
hospi[INVESTIGATOR_740594] s and assessed 
for seriousness. Admission to the hospi[INVESTIGATOR_34092] a pre -planned procedure or social or 
situational reasons (e.g., no place to st ay, lives too far away to come for hospi[INVESTIGATOR_6042]) 
will not be considered in -patient hospi[INVESTIGATOR_602] . 
• Persistent or significant disability or incapacity . 
• Congenital abnormality or birth defect . 
• It is an important medical event that may jeopardize the subject  or may require 
medical intervention to prevent one of the outcomes listed above.  
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical 
judgment, they may jeopardize the study subject and may require medical or surgical 
interve ntion to prevent one of the outcomes listed above. Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in- patient  
hospi[INVESTIGATOR_059] s, or the development of drug dependency. 
13.2.2. Reporting  of Adverse Events  
AEs spontaneously reported by [CONTACT_127205]/or in response to an open question from the study 
personnel or revealed by [CONTACT_7200].   
Non-serious AEs should be recorded on the eCRF from the time the subject has signed informed 
consent through the last study visit, unless otherwise specified. Any changes in the subject ’s 
status between signing informed consent, up to the time a dministration of the first dose of study 
drug will be recorded as a pre- treatment AE . Any AE  occurring after administration of the first 
dose of study drug will be considered a treatment emergent AE (TEAE).  
The AE term should be reported in standard medical terminology when possible.  
Any subject  who has an AE (whether serious or non- serious) or clinically significant test value  
will be evaluated by [CONTACT_978] [INVESTIGATOR_740595]/or followed up until the symptoms or values 
return to normal or to clinically acceptable levels, as judged by [CONTACT_978].  
Unless a diagnosis is available, signs and symptoms must be reported as individual AEs in the 
eCRF; a diagnosis is preferred.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 42 Confidential  For each AE, the investigator will evaluate and report the onset date, resolution  date , intensity, 
causality, action taken, serious outcome (if applicable), and whether or not it caused the subject 
to discontinue the study.  
Intensity will be assessed according to the N ational C ancer Institute  (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE), Version 5.0, 2017. The NCI Common 
Terminology Criteria for Adverse Events is a descriptive terminology which can be utilized for 
AE reporting. A grading (severity) scale is provided for each AE term. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of 
severity for each AE based on this general guideline:  
• Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
• Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental activities of daily living (ADL).  
• Grade 3 Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-care ADL.  
• Grade 4 Life -threatening consequences; urgent intervention indicated.  
• Grade 5 Death related to AE.  
It is important to distinguish between serious and severe AEs. Severity is a measure of inten sity 
whereas seri
ousness is defined by [CONTACT_740610] n [IP_ADDRESS]. An AE of
 severe intensity 
may not be conside
red serious significance (e.g., ‘severe’ headache ). Seriousness of AEs is based 
on the outcome/action of an AE. 
13.2.3. Reporting  of
 Serious Adv erse Events  
SAEs must be reported to the Sponsor or designee within [ADDRESS_1012376] be made 
immediately, irrespective of the extent of information available. In all cases, the PI [INVESTIGATOR_740596]. The Investigator may be required to provide supplementary information 
as requested by [CONTACT_4885]. 
When reporting SAEs, the following additional points shou ld be considered:  
• When the diagnosis of an SAE is known or suspected, the PI [INVESTIGATOR_740597], rather than as signs or symptoms; 
signs, symptoms and tests that support the diagnosis should be provided. 
• Death should not be reported as an SAE, but as an outcome of a specific SAE, unless 
the event preceding the death is unknown. If an autopsy was performed, the autopsy 
report should be provided. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012377] been met.  
The Sponsor will assess the expectedness of each SAE to the study treatment. The current 
Investigator’s Brochure will be used as the reference document to assess expectedness of the 
event to study drug. 
13.2.4. Relationship to Study Drug  
An Investigator who is qualified in medicine must make the determination of relationship to the 
investigational product for each AE (Unrelated or Related). The Investigator should decide 
whether, in his or her medical judgment, there is a reasonable possibility that the event may have 
been caused by [CONTACT_7198]. If no valid reason exists for suggesting a relationship, then the AE should be classified as “unrelated.” If there is any valid reason, even if 
undetermined, for suspecting a possible cause-and- effect relationshi p between the investigational 
product and the occurrence of the AE, then the AE should be considered “related.” 
The relationship of the AE to the study treatment will be based on the following two definitions: 
Not related : An AE is defined as “not related” if the AE is not judged to be associated with the 
study drug and is attributable to another cause. 
Related : An AE is defined as “related” where a causal relationship between the event and the 
study drug is a reasonable possibility (possibly or probably re lated). A reasonable causal 
relationship is meant to convey that there are facts (e.g., evidence such as dechallenge/  
rechallenge) or other clinical arguments to suggest a causal relationship between the AE and 
study treatment. 
13.3. Pregnancy Testing 
Should a s ubject  become pregnant during study participation, study drug dosing will be 
discontinued, and the subject  will be withdrawn from study. The Investigator must perform 
medical assessments as clinically indicated and continue to follow the subject  for at lea st 
[ADDRESS_1012378] be obtained. Pregnancy is not itself an AE or SAE; however, maternal/fetal complications or abnormalities must  be recorded as 
AEs or SAEs. The Investigator must complete a study -specific pregnancy form upon 
confirmation of a pregnancy. Pregnancy reporting forms will be provided to the study site.  
13.4. Pharmacokinetic Sampl ing 
Blood samples for pharmacokinetic (PK)  anlaysis  will be  collected  in all subjects. The 
procedural instructions will be provided in a separate pharmacokinetic instruction manual.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 44 Confidential  14. STUDY DISCONTINUATIONS  
14.1. Discontinuation of the Study  
The Sponsor has the right to terminate or to stop the study at any time. Should this be necessary, 
both the Sponsor and the Investigator will ensure that proper study discontinuation procedures are completed. The entire study will be stopped if: 
• Evidence has emerged that, in the collective opi[INVESTIGATOR_740598], makes the continuation of the study unnecessary or unethical. 
• The stated objectives of the study are achieved.  
• The Sponsor discontinues the development of the study drug. 
Regardless of the reason for  withdrawal , all data available for the subje ct at the time of 
discontinuation of follow-up must be recorded in the eCRF. All reasons for discontinuation of treatment must be documented.  
14.2. Early Withdrawal of Study Subject s 
The Investigator will make every reasonable effort to keep each subject in the study; however, a subject may voluntarily withdraw from study participation at any time. If the subject  withdraws 
consent and discontinues from the study, the Investigator will attempt to schedule an Early 
Withdrawal Visit as soon as possible, determine th e reason for discontinuation , and record the 
reason in the subject’s study records and i n the eCRF.   
If at any time during the study, the Investigator determines that it is not in the best interest of the subject to continue, the subject will be discontinu ed from participation. The Investigator may  
discontinue a subject at any time if medically necessary. The Investigator may discontinue a 
subject ’s participation if the subject  has failed to follow study procedures or , to keep follow -up 
appointments. Prior to discontinuing a subject from study participation, the Investigator will 
discuss his/her intentions with the Sponsor ’s Medical Monitor or designee. Appropriate 
documentation in the subject ’s study record and eCRF regarding the reason for discontinuation 
must be completed.  
All subjects who fail to return to the study site for the required follow -up visits will be contact[CONTACT_294731](s) why the subject fai led to return for the necessary visit or 
elected to discontinue from the study. If a subject  is unreachable by [CONTACT_34675] a minimum 
of two documented attempts (one attempt on two different days), a registered letter will be sent 
requesting that subject contact [CONTACT_716091]-up.  
Subjects will be discontinued early from the study if any of the following occur: 
• Withdrawal of informed consent ( subject ’s decision to withdraw for any reason). 
• Any clinical AE , laboratory abnormality, or inter-current illness which, in the opi[INVESTIGATOR_18959], indicates that continued treatment and/or participation in the study 
is not in the best interest of the subject . 
• Death.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 45 Confidential  • Serious protocol violation, including pers istent non -compliance , subjects requiring 
prohibited medication s or procedures allowing subjects to receive the appropriate 
medical  attention. In such cases, the Investigator must contact [CONTACT_95346], as the final decision to withdraw the subje ct will be taken by [CONTACT_1034]. 
• Discontinuation of the study by [CONTACT_1034]. 
14.3. Study Drug Discontinuation  
Subjects who  discontinue or have their study drug discontinued prematurely should continue  to 
have all protocol- specified safety assessments and end of study procedures collected .  
The Investigator should stop study drug treatment in the following instances: 
• Inter -current illness that would, in the judgment of the Investigator, affect 
assessments of clinical status to a significant degree.  
• Any AE  which is clinically significant, is deemed persistent, is probably or definitely 
related to study drug in the judgment of the Investigator.  
• Unacceptable toxicity.  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 46 Confidential  15. STATISTIC AL CONSIDERATIONS  
15.1. General Statistical Methodology  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a separate 
document. The SAP will be finalized prior to unblinding of the study treatments. 
All statistical processing will be performed using SAS® unless otherwise stated. No interim 
analyses are planned. All statistical tests will be one -sided  and will be performed at the 0.05 level 
of significance.  
Descriptive statistics will be used to provide an overview of the efficacy and safety results. 
For categorical parameters, the number and percentage of subjects in each category will be 
presented. For continuous parameters, descriptive statistics will include n (number of subjects), 
mean, standard deviation (SD), median, minimum,  and maximum. Appropriate inferential 
statistics will be used for the primary and secondary efficacy variables.  
The primary method of handling missing efficacy data will be  based on MCMC; additional 
details, including details  on sensitivity analyses will be provided in the SAP.   
The pruritus -NRS weekly mean will b e calculated as follows: The mean of each subject ’s 
baseline and post -baseline pruritus -NRS scores will be computed for each week based on the 
previous [ADDRESS_1012379] has 3 or fewer pruritus -NRS responses, the 
mean value for that item will be considered missing.  All pruritus -NRS efficacy endpoint analyses 
will be conducted on the weekly mean.  
Demographic data will be summarized  by [CONTACT_2070]. Subjects’ 
baseline characteristics related to efficacy analyses will be compared with descriptive statistics 
among treatment groups to ensure comparable results.  
The number of subjects in each analysis set will be summarized. Reasons for study withdrawal during the blinded study will be summarized using frequencies and percentages by [CONTACT_1570]. 
15.2. Populations Analyzed 
All subjects who are randomized will be included in the intent- to-treat ( ITT) population.  
Per-protocol ( PP) population: All subjects in the ITT population who complete the Week 8 
evaluation without any significant protocol violations 
PK population: All subjects who had blood collected for PK analysis will be included in the PK 
population.  
All subjects who are randomized and receive at least one confirmed dose of study drug will be 
included in the safety population. 
The primary efficacy analysis and the analysis of all secondary endpoints will be performed 
using the ITT population Additional supportive efficacy analyses will be performed using the PP 
population. In all efficacy analysis, subjects will be included in the treatment arm to which they 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012380] applied  80% to 120% of the expected number of 
applications while enrolled in the study.  
15.4. Efficacy Measures  
15.4.1. Primary Efficacy Analysis 
The primary efficacy analysis will be conducted with an analysis of variance (ANOVA) model with the p ercentage change from  Baseline to Week [ADDRESS_1012381] at the alpha=0.05 level of significance. 
15.4.2. Secondary Efficacy Analyses 
All secondary endpoints defined as the percentage change from baseline will be analyzed using 
the same type of ANOVA model as specified for the primary analysis.  All change from baseline 
secondary endpoints will be analyzed using a nalysis of covariance (ANCOVA) models with 
treatment group  and the randomization stratification variable as factor s and with the baseline 
value of the corresponding endpoint as a covariate. Secondary endpoints that are defined as 
proportion variables will be analyzed using Pearson’s chi- square test or (if more than 25% of 
expected cell frequencies are less than 5) Fisher’s exact test.  All secondary analyses will be 
conducted using one- sided  tests at the alpha=0.05 level of significance, with no adjustments for 
multiplicity.  
15.5. Adverse Events 
All AEs that occur during the study will be recorded and classified on the basis of Medical Dictionary for Regulatory Activities (MedDRA) terminology. TEAEs are defined as AEs with an onset on or after the date of the first study drug application. AEs noted prior to the first study 
drug administration that worsen after baseline will also be reported as AEs and included in the summaries.  
All information pertaining to an AE noted during the study will be listed by [CONTACT_1130], de tailing the 
verbatim term given by [CONTACT_18370], preferred term, system organ class, onset date, resolution date, severity, seriousness, action taken, outcome and drug relatedness. The event onset will also be shown relative (in number of days) to date of first application.  
Treatment -emergent AEs will be summarized by [CONTACT_1570], the number of subjects 
reporting a TEAE, system organ class, preferred term, severity, relationship to study drug 
(causality) and seriousness. When summarizin g AEs by [CONTACT_42564], each subject 
will be counted once within a system organ class or a preferred term by [CONTACT_740611].  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012382] of subjects who prematurely 
discontinue from the study due to an AE will be provided. 
15.5.1. Local Skin Reactions  
Local Skin Reaction  assessment s (LSRs) include burning/stinging, pruritus, edema/swelling, 
erythema, dryness, and scaling. LSRs will be scored as 0 (None), 1 (Mild), 2 (Moderate) or 3 
(Severe).  
LSRs will be summarized by [CONTACT_16750]. A by -subject listing of subject s 
with any LSR scored as [ADDRESS_1012383] listing.  
Descriptive statistics by [CONTACT_740612]: heart rate (HR), RR duration, QRS duration, PR duration, QT duration and QTcF  
and Q TcB duration.  
15.7. Pharmacokinetic Analysis  
Plasma concentration data will be tabulated and summarized (geometric mean, arithmetic mean, 
minimum, maximum, SD, and % coefficient of variation) by [CONTACT_143242].   
15.8. Sample Size Determination  
The assumed true standard deviation of the percentage change from Baseline to Week 8 in the 
EASI score is 50%. Based on the use of a one- sided test  at the alpha=0.05 level of significance, a 
total sample size of 118 subjects (5 9 subjects/ treatment arm) will provide  greater than  90% 
power to detect a mean between -group difference of 30 percentage points. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012384] the trial and site 
staff are trained on the protocol.  The study w ill be discussed with the investigator(s) and other 
personnel with regard to their responsibilities , protocol adherence, and the responsibilities of the 
Sponsor or its representatives.  
During the study, the Sponsor or its designee will have regular contac t with the study site to:  
• Provide information and support to the investigator(s). 
• Confirm that facilities remain acceptable . 
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report form s, and that investigational product 
accountability checks are being performed . 
• Perform source data verification.  This includes a comparison of the data in the case 
report forms with the subject’s medical records at the hospi[INVESTIGATOR_7117], and other 
recor ds relevant to the study. This will require direct access to all original records for 
each subject  (e.g., clinic charts).  
• Record and report any protocol deviations not previously identified.  
• Confirm AEs and SAEs have been properly documented on e CRFs and confirm all  
SAEs have been forwarded to the Sponsor or its designee and, as appropriate, 
forwarded to the institutional review board  (IRB). 
Subject confidentiality will be always maintained . The monitor will be available between visits if 
the investigator(s) or other staff needs information or advice.  The Investigator a grees to 
cooperate with the study monitor to ensure that any problems detected during the monitoring 
visits are resolved.  
16.2. Audits and Inspections  
Authorized representatives of the Sponsor or its designee, a regulatory authority, an Independent 
Ethics Committee  (IEC)  or an IRB may visit the site to perform audits or inspections, including 
source data verification.  The purpose of a Sponsor’s audit or inspection is to systematically and 
independently examine all study- related activities and documents to determine whether these 
activities were conducted, and data were recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice guidelines of the International Council for  Harmonisation, 
and any applicable regulatory requirements. The investigator should contact [CONTACT_740613] a regulatory agency about an inspection. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 50 Confidential  17. ETHICS  
17.1. Ethics Review  
The final study protocol, including the final version of the Informed Consent Form (ICF) , must 
be approved or given a favorable opi[INVESTIGATOR_46626], as appropriate.  The 
investigator must submit written approval to the Sponsor or its designee before he or she can 
enroll any subject into the study.  
The Principal Investigator [INVESTIGATOR_740599], in accordance with local requirements.  In addition, the IRB or IEC must approve all 
advertising used to recruit subjects f or the study. The protocol must be re -approved by [CONTACT_49918], as local regulations require. 
The Principal Investigator [INVESTIGATOR_740600]. The Sponsor or its designee will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB or IEC according to local regulations and guidelines. 
17.2. Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable with all 
local regulatory requirements. 
17.3. Written Informed Consent 
The Prin cipal Investigator(s) at each study site will ensure that the subject is given full and 
adequate oral and written information about the nature, purpose, possible risk, and benefit of the 
study. Subject s must also be notified that they are free to discontinue from the study at any time.  
The subject should be given the opportunity to ask questions and allowed time to consider the information provided.  
The subject’s signed and dated informed consent must be obtained before conducting any study 
procedures. 
The Principal Investigator(s) must maintain the original, signed ICF . A copy of the signed ICF  
must be given to the subject . 
17.4. Compliance with the Protocol and Protocol Amendments 
The study shall be conducted as described in this protocol. All revisions to the protocol must be 
prepared by [CONTACT_1034]. The Investigator will not implement any deviation or change to the 
protocol without prior review and documented approval/favorable opi[INVESTIGATOR_5698]/EC of 
an Amendment, except where necessary to eliminate an immediate hazard(s) to study subjects. Any significant deviation must be documented and submitted to the IRB/EC; the Sponsor or 
designee; and, if required, Regulatory Authority (ies).  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 51 Confidential  Documentation of approval signed by [CONTACT_12715](s)/I EC(s) must be 
sent to the Sponsor and/or designee. 
17.5. Study Documentation and the Case Report Form  
The Investigator is responsible for ensuring that data are properly recorded in the eCRFs and on 
related documents. All entries must be supported by [CONTACT_423]’s medical records or source 
notes. The Investigator who has signed the protocol signature [CONTACT_740615]. 
All Investigator observations/assessments must be reported in the eCRF. The original reports and 
any traces and films must be reviewed, signed, and dated and retained by [CONTACT_294741].  
An Investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all o bservations and other data pertinent to the investigation on each individual treated 
with the investigational product or entered as a control in the investigation. Data reported in the 
eCRFs that are derived from source documents must be consistent with th e source documents or 
the discrepancies must be explained.  
The Investigator must certify that the data are complete and accurate at the time the subject  ends 
the study or as instructed by [CONTACT_656561].  
  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012385] a quality assurance audit.  
  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012386] the Sponsor prior to destroying any records associated with 
the study. Following the study close-out visit, data will be provided to the Investigator to store 
with the Investigator’s study file for archiving purposes.  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 54 Confidential  20. PUBLICATION POLICY  
Publication rights are addressed in the Investigator and/or CRO agreements, as applicable. 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012387] OF REFERENCES  
Cushing L, Winkler A, Jelinsky SA, et al. (2017). IRAK4 kinase activity controls Toll- like 
receptor -induced inflammation through the transcription factor IRF5 in primary human 
monocytes. J Biol Chem , 292(45), [ZIP_CODE]-[ZIP_CODE]. 
https://doi.org/10.1074/jbc.M117.796912  
Dinarello CA. (2018). Overview of the IL- 1 family in innate inflammation and acquired 
immunity. Immunol Rev , 281(1), 8-27. https://doi.org/10.1111/imr.[ZIP_CODE]  
Dou H, Song Y, Liu X, et al. (2014). A novel benzenediamine derivate rescued mice from 
experimental sepsis by [CONTACT_740614]4. Am J Respir 
Cell Mol Biol, 51(2), 191-200. https://doi.org/10.1165/rcmb.2013-0411OC  
Fraczek J, Kim TW, Xiao H, et al. (2008). The kina se activity of IL -1 receptor- associated kinase 
4 is required for interleukin -1 receptor/toll -like receptor -induced TAK1-dependent 
NFkappaB activation. J Biol Chem , 283(46), [ZIP_CODE]-[ZIP_CODE]. 
https://doi.org/10.1074/jbc.M804779200  
Gottlieb A. Bermekimab is a rapid and effective treatment for atopic dermatitis, including 
marked reduction in pruritis. Presented at: 28th European Academy of Dermatology and Venereology Congress; Oct. 9-13, 2019; Madrid. 
Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy Volunteers. July 2005. FDA website. https://www.fda.gov/regulatory- information/search -fda-guidance- documents/estimating -
maximum- safe-starting -dose- initial -clinical -trials -therapeutics-adult- healthy-volunteers. 
Accessed 03 June 2022. 
Hanel KH, Pfaff CM, Cornelissen C, et al. (2016). Control of the Physical and Antimicrobial 
Skin Barrier by [CONTACT_238631]-31- IL-1 Signaling Network. J Immunol , 196(8), 3233-3244. 
https://doi.org/10.4049/jimmunol.1402943  
Hon KL, Tsang KY, Kung JS, Leung TF, Lam CW, Wong CK. (2017). Clinical Signs, 
Staphylococcus and Atopic Eczema- Related Seromarkers. Molecules, 22(2). 
https://doi.org/10.3390/molecules22020291  
Hulshof L, Hack DP, Hasnoe QCJ, et al. (2019). A minimally invasive tool to study immune 
response and skin barrier in children with atopic dermatitis. Br J Dermatol , 180(3), 621-
630. https://doi.org/10.1111/bjd.[ZIP_CODE]  
Imai Y. (2019). Interleukin -33 in atopic dermatitis. J Derm atol Sci , 96(1), 2-7. 
https://doi.org/10.1016/j.jdermsci.2019.08.006  
Jensen LE. (2010). Targeting the IL-1 family members in skin inflammation. Curr Opin Investig 
Drugs , 11(11), 1211-1220. https://www.ncbi.nlm.nih.gov/pubmed/21157640  
Kawagoe T, Sato S, Jung A, et al. (2007). Essential role of IRAK-4 protein and its kinase activity 
in Toll- like receptor -mediated immune responses but not in TCR signaling. J Exp Med , 
204(5), 1013-1024. https://doi.org/10.1084/jem.20061523  
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : 11 May 2023 56 Confidential  Kim TW, Staschk e K, Bulek K, et al. (2007). A critical role for IRAK4 kinase activity in Toll-
like receptor -mediated innate immunity. J Exp Med , 204(5), 1025-1036. 
https://doi.org/10.1084/jem.20061825  
Koziczak -Holbro M, Littlewood-Evans A, Pollinger B, et al. (2009). The critical role of kinase 
activity of interleukin -1 receptor -associated kinase 4 in animal models of joint 
inflammation. Arthritis Rheum , 60(6), 1661-1671. https://doi.org/10.1002/art.[ZIP_CODE]  
Li S, Strel ow A, Fontana EJ, Wesche H. (2002). IRAK- 4: a novel member of the IRAK family 
with the properties of an IRAK -kinase. Proc Natl Acad Sci U S A , 99(8), 5567-5572. 
https://doi.org/10.1073/pnas.082100399  
Newton K, Dixit VM. (2012). Signaling in innate immunit y and inflammation. Cold Spring Harb 
Perspect Biol , 4(3). https://doi.org/10.1101/cshperspect.a006049  
Nutan FN, Kanwar AJ, Parsad D. (2012). The effect of topi[INVESTIGATOR_740601] 1beta levels in patients with atopic dermatitis. J Eur Acad Dermatol Venereol , 
26(8), 1020-1022. https://doi.org/10.1111/j.1468-3083.2011.[ZIP_CODE].x  
Ospelt C, Gay S. (2010). TLRs and chronic inflammation. Int J Biochem Cell Biol, 42 (4), 495-
505. https://doi.org/10.1016/j.biocel.2009.10.010  
Patra  MC, Choi S. (2016). Recent Progress in the Molecular Recognition and Therapeutic 
Importance of Interleukin- 1 Receptor -Associated Kinase 4. Molecules, 21(11). 
https://doi.org/10.3390/molecules21111529  
Pi[CONTACT_1137] C, von Bernuth H, Ghandil P, et al. (2010). Cli nical features and outcome of patients with 
IRAK-4 and MyD88 deficiency. Medicine (Baltimore), 89(6), 403-425. 
https://doi.org/10.1097/MD.0b013e3181fd8ec3  
Savinko T, Matikainen S, Saarialho-Kere U, et al. (2012). IL- 33 and ST2 in atopic dermatitis: 
expres sion profiles and modulation by [CONTACT_319088]. J Invest Dermatol , 132(5), 
1392-1400. https://doi.org/10.1038/jid.2011.446  
Suarez-Farinas M, Ungar B, Correa da Rosa J, et al. (2015). RNA sequencing atopic dermatitis 
transcriptome profiling provides in sights into novel disease mechanisms with potential 
therapeutic implications. J Allergy Clin Immunol , 135(5), 1218-1227. 
https://doi.org/10.1016/j.jaci.2015.03.003  
Wang  Z, Wesche H, Stevens T, Walker N, Yeh WC. (2009). IRAK- 4 inhibitors for 
inflammation. Curr Top Med Chem , 9(8), 724-737. 
https://doi.org/10.2174/156802609789044407  
 
Evommune, Inc.  
EVO101 Topi[INVESTIGATOR_740579]101 -AD001  
Protocol : [ADDRESS_1012388] AD Mappi[INVESTIGATOR_740587]  
 
